Lose Weight with the Caralluma Fimbriata Reported by Dr. Oz
Are you looking for a natural weight loss supplement that has centuries of use behind it as what is labeled as a famine food? According to a recent episode of The Dr. Oz Show that tackles weight loss by curbing your cravings while dieting, Dr. Oz reveals a new weight loss supplement called Caralluma fimbriata that many testify has helped them lose weight.
According to Dr. Oz, ghrelin is a well-known hunger hormone that you experience the first thing in the morning that signals the body that it’s time to eat and nourish the body, Unfortunately, when ghrelin levels are up, they can trigger cravings for unhealthy foods such as sodium-rich carbohydrate-based snacks that will not only raise your blood pressure, but also add unwanted pounds—fast!
To nip these salt cravings in the bud, Dr. Oz recommends trying 500 milligrams of a Caralluma fimbriata supplement twice a day as a ghrelin-inhibiting weight loss supplement.
So just what is Caralluma fimbriata?
A member of the cactus family, Caralluma fimbriata is a succulent plant that has been used for centuries in India as a portable food while hunting due to its very effective appetite suppressing properties. According to one study, hunters would eat only a handful or so of the cacti that would then suppress hunger for days at a time during prolonged hunts.
Its label as a “famine food” originates of its use during famines to stave off hunger pains among starving people in rural areas where this cactus-like plant with its characteristic star-shaped flower grows wild.
Essentially, Caralluma fimbriata is consumed as a staple vegetable primarily in tribal India that is either cooked like a regular vegetable dish garnished with salt and spices, used in pickled preserves, or eaten raw.
Because of its well-known appetite curbing properties, scientists have made extracts of the plant to study and develop as a potential weight loss supplement.
In a recent article published in the journal Complementary Therapies in Medicine, a randomized, double blind placebo controlled clinical trial involving forty-three overweight or obese adults aged 29-59 years were used to determine the effectiveness of Caralluma fimbriata extract in conjunction with diet and moderate exercise.
In the study, the participants were randomly divided into two groups of which for a period of 12 weeks one group was provided with 500 milligram capsules twice a day of Caralluma fimbriata extract while the other group was given a placebo. Diet and physical activity levels were monitored of all study participants to limit external factors that might skew the study data.
At the end of the 12-week period the data was analyzed and revealed that while both groups lost weight and body fat, the Caralluma fimbriata extract group did significantly better:
• 33 participants completed the study with the primary outcome of a statistically significant decrease in waist measurement in the Caralluma fimbriata extract group.
• The Caralluma fimbriata extract group lost on average 2 and ½ inches compared to 1 inch on average in the placebo group.
• Waist to hip ratio significantly improved in Caralluma fimbriata extract group.
• Significant appetite suppression was evidenced in the Caralluma fimbriata extract group.
The conclusion reached by the scientists is that supplementation with Caralluma fimbriata extract in conjunction with controlling overall dietary intake and physical activity may potentially play a role in curbing central obesity and improving the metabolic risk profile of dieters who take this supplement.
To discover what sources of Caralluma fimbriata extract are recommended to buy for weight loss, go to this article on Caralluma fimbriata sources.
Here is an additional article about a similar cactus-like plant used by Kalahari Bushmen to suppress appetite that has been reported to work successfully as a weight loss supplement ingredient.
Image Source: Courtesy of PhotoBucket
“A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomized controlled clinical trial” Complementary Therapies in Medicine Vol. 21, Issue 3, Pages 180-189, June 2013.